

# CHMP opinions for medicines for human use


2013

## Positive opinions in 2013\*


<b>Total</b>	<b>New (non-orphan) medicines</b>	<b>Orphan medicines**</b>
<b>81</b>	<b>44</b>	<b>11</b>
<b>Biosimilars</b>	<b>Advanced therapies</b>	<b>Generic, hybrid and informed-consent applications</b>
<b>4</b>	<b>2</b>	<b>20</b>

## Trends

Positive opinions  
(2009–2013)



Orphan medicines  
(2009–2013)



Year	New (non-orphan) medicines	Orphan medicines	Biosimilars	Generic, hybrid and informed-consent applications	Withdrawals prior to opinion	Negative opinions
2009	53	7	0	57	14	8
2010	20	4	1	26	12	2
2011	38	4	0	45	13	4
2012	30	8	0	19	10	8
2013	46***	11**	4	20	8	5

\* These figures include two positive opinions that were adopted following re-examination procedures.

\*\* This figure includes one hybrid product and one well-established-use product not counted in the other categories.

\*\*\* This figure includes two advanced therapies.